Iovance Biotherapeutics has now climbed 41% in a month and the Street is finally chasing it higher — yet the short book, week after week, refuses to break.
The most notable development this week is on the analyst side. Mizuho raised its target to $11 on Tuesday, fresh off Barclays lifting to $13 and Citizens pushing to $8 last week — all three maintaining positive ratings. The direction of travel is unambiguous: analysts who were anchored at $4-$5 in the spring are now running targets well above the current price of $7.03. The consensus mean sits at $9.33, implying over 30% upside from here. Bulls point to the FDA-approved TIL therapy in post-checkpoint melanoma, a growing pipeline, and a commercial launch that surprised to the upside at the August 6 print — a print that sent the stock up 46% in a single session. Bears remain focused on manufacturing costs, the absence of a clear path to profitability, and competition in the TIL market. The ORTEX short score at 70.9 sits in the 11th percentile for short positioning rank, reflecting how heavily this name remains loaded with skeptics relative to the broader universe.
The positioning picture has barely moved in three weeks, which is itself the story. Short interest is 22.7% of the free float — roughly 90 million shares — up fractionally on the week despite the stock adding 8%. Bears have returned perhaps 33 million shares since the July peak above 121 million, but covering has been slow relative to the rally's magnitude. What keeps this from becoming a mechanical squeeze is the borrow market: availability has loosened further to 147%, up about 19% on the week, meaning the lending pool holds nearly 1.5 shares available for every share already borrowed. Cost to borrow has drifted to 0.47%, down 7% on the week and down roughly 40% over the past month. That combination — heavy short interest, easy borrow, low cost — describes a short book that is painful on paper but not forced. Bears can add exposure cheaply if they choose. So far, incrementally, they are not.
Options have shifted slightly more defensive as the rally has extended. The put/call ratio has climbed to 0.35, near the top of its 52-week range and running about 1.4 standard deviations above its 20-day average. That is not an extreme reading, but the directional move is clear: as the stock pushed higher this week, options traders added more downside protection rather than leaning into calls. The 52-week high on the PCR is 0.37, so the current reading is approaching the most defensive stance of the past year. That tension — analysts raising targets while options traders hedge more aggressively — captures the split personality this stock has carried since August 6.
On the institutional side, BlackRock added nearly 5.9 million shares in the most recent reporting period, bringing its stake to 8.2% of the company. State Street added over 7 million shares in the same window. Those are meaningful additions from passive-leaning managers, but they reflect index-driven flows as much as active conviction. The insider activity is lower-signal — the CFO and CCO both sold small parcels in early August following award grants, a routine tax-driven pattern with significance scores of 1. No director buying has appeared to reinforce the bull case at the stock level.
The next earnings event is scheduled for November 6. The August print established a high bar: a 46% single-day move followed by a further 50% gain over the following five days. Whether the commercial ramp for Amtagvi continues to beat expectations — and whether manufacturing costs begin to compress — will determine whether the remaining short book finally concedes or digs in further into year-end.
See the live data behind this article on ORTEX.
Open IOVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
